| Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables |
209 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials |
177 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial |
133 |
| Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials |
100 |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis |
96 |
| Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis |
91 |
| Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies |
87 |
| Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis |
83 |
| Type 2 diabetes in adolescents and young adults |
81 |
| Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial |
80 |
| Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK |
80 |
| Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial |
75 |
| Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial |
74 |
| Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study |
69 |
| Glycaemic variability in diabetes: clinical and therapeutic implications |
68 |
| Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement |
67 |
| Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis |
63 |
| Interventions to prevent global childhood overweight and obesity: a systematic review |
62 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial |
56 |
| Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study |
53 |
| Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study |
52 |
| Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications |
49 |
| Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank |
48 |
| Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial |
44 |
| Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study |
41 |
| Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies |
40 |
| Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study |
40 |
| Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data |
40 |
| Incidence and progression of diabetic retinopathy: a systematic review |
40 |
| Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management |
39 |
| Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial |
39 |
| Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial |
39 |
| Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies |
38 |
| Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial |
37 |
| Prevalence of obesity, hypertension, and diabetes, and cascade of care in sub-Saharan Africa: a cross-sectional, population-based study in rural and urban Malawi |
37 |
| Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials |
37 |
| Metabolically healthy obesity: the low-hanging fruit in obesity treatment? |
37 |
| Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial |
34 |
| Diabetes structured self-management education programmes: a narrative review and current innovations |
34 |
| Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment |
33 |
| Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial |
32 |
| Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial |
32 |
| 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase randomised controlled trial |
30 |
| Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial |
30 |
| Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial |
29 |
| The challenge of modulating beta-cell autoimmunity in type 1 diabetes |
29 |
| Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial |
29 |
| Epidemiology and determinants of type 2 diabetes in south Asia |
29 |
| Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management |
28 |
| Mean HbA(1c), HbA(1c) variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study |
28 |
| Progress and challenges in anti-obesity pharmacotherapy |
26 |
| Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial |
26 |
| Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014 |
26 |
| Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial |
26 |
| Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study |
26 |
| Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study |
25 |
| Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study |
25 |
| Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study |
24 |
| Precision nutrition for prevention and management of type 2 diabetes |
23 |
| Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial |
22 |
| Do sulphonylureas still have a place in clinical practice? |
21 |
| Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial |
21 |
| Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies |
20 |
| Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data |
20 |
| Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial |
19 |
| Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine |
19 |
| Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial |
19 |
| The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982-2012: a cross-sectional population-based study |
19 |
| The physiology of endocrine systems with ageing |
18 |
| Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial |
18 |
| Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study |
18 |
| LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial |
18 |
| Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population |
18 |
| Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis |
18 |
| Economic development and the nutritional status of Chinese school-aged children and adolescents from 1995 to 2014: an analysis of five successive national surveys |
18 |
| Advances in the medical treatment of Cushing's syndrome |
17 |
| Clinical management of type 2 diabetes in south Asia |
17 |
| Frailty and the endocrine system |
17 |
| Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial |
16 |
| Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial |
16 |
| Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden |
16 |
| Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial |
16 |
| Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase equivalence trial |
16 |
| Autoimmune thyroid disease during pregnancy |
16 |
| Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an occupational cohort study in Brazil |
15 |
| Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial |
15 |
| SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks |
15 |
| Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study |
15 |
| Association of preconception serum 25-hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study |
14 |
| Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study |
14 |
| Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycaemia in Bangladesh (DMagic): a cluster-randomised controlled trial |
14 |
| Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 x 2 factorial, double-blind, randomised controlled trial |
13 |
| Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980793 adults from 68 prospective studies |
13 |
| Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials |
13 |
| Precision medicine in the management of type 2 diabetes |
13 |
| Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial |
13 |
| Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers |
13 |
| Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial |
13 |
| Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention |
12 |
| Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials |
12 |
| Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study |
12 |
| Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES) |
12 |
| Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study |
12 |
| Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial |
12 |
| Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial |
11 |
| New pharmacological strategies for protecting kidney function in type 2 diabetes |
11 |
| The burden of diabetes and use of diabetes care in humanitarian crises in low-income and middle-income countries |
11 |
| Association between maternal pre-pregnancy obesity and preterm birth according to maternal age and race or ethnicity: a population-based study |
10 |
| Blood glucose meters and test strips: global market and challenges to access in low-resource settings |
10 |
| Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial |
10 |
| Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort |
9 |
| Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies |
9 |
| Bone health during endocrine therapy for cancer |
9 |
| Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial |
9 |
| Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? |
9 |
| Gender-affirming hormones and surgery in transgender children and adolescents |
9 |
| Metabolic health in the Middle East and north Africa |
9 |
| Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial |
8 |
| Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial |
8 |
| Ageing and endocrinology 3 Clinical aspects of thyroid function during ageing |
8 |
| Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase multicentre, open-label, single-arm trial |
8 |
| Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child' s epigenome and later risk of disease |
8 |
| Distal technologies and type 1 diabetes management |
8 |
| A genetic approach to evaluation of short stature of undetermined cause |
8 |
| Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study |
7 |
| Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia |
7 |
| Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study |
7 |
| Aiding sleep in type 2 diabetes: therapeutic considerations |
7 |
| Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial |
6 |
| Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase randomised controlled trial |
6 |
| Optimisation of follow-up after metabolic surgery |
6 |
| Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial |
6 |
| Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment |
6 |
| Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial |
5 |
| Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials |
5 |
| Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study |
4 |
| Challenges associated with providing diabetes care in humanitarian settings |
4 |
| Rethinking good cholesterol: a clinicians' guide to understanding HDL |
4 |
| A clinical algorithm to diagnose differences of sex development |
4 |
| Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study |
4 |
| Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial |
2 |
| Cushing's disease-from Minnie G to key issues in the early 21st century |
2 |
| The role of blood volume in cardiac dysfunction and reduced exercise tolerance in patients with diabetes |
2 |
| Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial |
0 |
| Television The truth in beige and white |
0 |
